Drug Profile
Methylprednisolone sodium succinate liposomal - LipoCure
Alternative Names: LC 200; Methylprednisolone sodium succinate liposomalLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator LipoCure
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antirheumatics; Corticosteroids
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple sclerosis; Optic neuritis; Rheumatoid arthritis; Systemic lupus erythematosus
- No development reported Falciparum malaria; Leukaemia
Most Recent Events
- 31 Aug 2023 Methylprednisolone sodium succinate liposomal (LC 200) is still in preclinical phase for Multiple sclerosis, Optic neuritis, Rheumatoid arthritis, Systemic lupus erythematosus in Isreal (LipoCure pipeline, August 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Falciparum-malaria in Israel (IV, Injection)
- 28 May 2020 No recent reports of development identified for preclinical development in Leukaemia in Israel (IV, Injection)